ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03836859
Recruitment Status : Completed
First Posted : February 11, 2019
Last Update Posted : February 11, 2019
Sponsor:
Collaborator:
Cromsource
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

Brief Summary:

The primary objective of this study is to assess the safety and tolerability of a single short-term and a multiple dose scheme of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity.

The secondary objective of this study is to assess the pharmacokinetics of single and multiple doses of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity.


Condition or disease Intervention/treatment Phase
Neurotrophic Keratitis Drug: rhNGF 20μg/mL Other: Placebo Phase 1

Detailed Description:

This is a Phase I, randomized, double-masked, placebo-controlled eye drops administration study of rhNGF in healthy male and female subjects of Japanese Ethnicity to evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops (rhNGF 20 μg/mL -formulation containing L-methionine as excipient) versus vehicle (vehicle control containing L-methionine as excipient) in Healthy Male and Female Volunteers of Japanese Ethnicity. The IMP was administered in the study Eye with the following scheme:

Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).

Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).

Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.

The reference product (vehicle) was administered in the study eye with the following scheme:

Day 1: One drop instilled into study eye (35 μL, corresponding to 0 μg of rhNGF].

Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 0 μg of rhNGF).

A total dose of placebo vehicle in the study eye will be 31 drops (1085 μL, 0 μg rhNGF) over 6 days.

For the Fellow (Non-Study) Eye for all subjects, the scheme was the following:

Day 1: One drop instilled into a fellow eye (35 μL, corresponding to 0 μg of rhNGF).

Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into a fellow eye (210 μL, corresponding to 0 μg of rhNGF).

A total dose of placebo vehicle in the fellow eye will be 31 drops (1085 μL, 0 μg rhNGF) over 6 days.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Quadruple (subject, Investigator, site staff and Sponsor's clinical research personnel)
Primary Purpose: Treatment
Official Title: Phase I, Randomized, Double-masked, Placebo-controlled Study (6 Days) to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Male and Female Volunteers of Japanese Ethnicity
Actual Study Start Date : March 30, 2018
Actual Primary Completion Date : June 1, 2018
Actual Study Completion Date : June 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: rhNGF 20μg/mL
rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
Drug: rhNGF 20μg/mL

Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).

Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).

Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.

Other Name: cenegermin

Placebo Comparator: Placebo
Vehicle: formulation containing L-methionine as excipient.
Other: Placebo
Vehicle: formulation containing L-methionine as excipient.




Primary Outcome Measures :
  1. Incidence of treatment emergent adverse events (TEAEs). [ Time Frame: 60 days from study initiation date to study completion date. ]
    TEAEs were defined as an adverse event (AE), which started after first dose of study treatment. These comprise AEs during the treatment and follow-up period.

  2. Incidence of treatment emergent adverse events during first dose schedule (TEAEs Dose 1). [ Time Frame: 60 days from study initiation date to study completion date. ]
    TEAEs Dose 1 were defined as TEAEs, which started after first dose of study treatment and before administration of the first dose at Treatment Day 2.

  3. Incidence of treatment emergent adverse events during second dose schedule (TEAEs Dose 2). [ Time Frame: Day 2 and before Follow Up 1 at day 7 ]
    TEAEs Dose 2 were defined as TEAEs, which started on/after the first dose at Treatment Day 2 and before Follow-Up Day 7 visit.

  4. Change from baseline in Visual Analogue Scale (VAS) ocular tolerability scores in study eye [ Time Frame: Treatment Day 2 pre-dose ]
    Baseline was defined as the pre-treatment assessment visit. On VAS scale, 0 means no symptoms and 100 means the worst possible discomfort.

  5. Change from baseline in Visual Analogue Scale (VAS) ocular tolerability scores in study eye [ Time Frame: Treatment Day 2 8 hours, Day 3 pre-dose, Day 6 pre-dose, Day 6 8 hours, Day 7 (Follow Up 1), Day 8 (Follow Up 2), Day 16 (Follow Up 3) ]
    Baseline was defined as the pre-treatment assessment at the Treatment Day 2 visit. On VAS scale, 0 means no symptoms and 100 means the worst possible discomfort.


Secondary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: Treatment Day 1 and Day 2 pre-dose ]
    The parameter mentioned above parameters was based on assessments on day 1 and pre-dose of day 2

  2. Time to reach Cmax (tmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On day 1 and pre-dose of day 2 ]
    The parameter mentioned above parameters was based on assessments on day 1 and pre-dose of day 2

  3. Time delay between the time of dosing and time of appearance of concentration in the sampling compartment (tlag) of single dose regimen - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On day 1 and pre-dose of day 2 ]
    The parameter mentioned above parameters was based on assessments on day

  4. Peak Plasma Concentration (Cmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: Pre-dose on day 2 ]
    The parameter mentioned above parameters was based on assessments starting with pre-dose of day 2

  5. Time to reach Cmax (tmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: Pre-dose on day 2 ]
    The parameter mentioned above parameters was based on assessments starting with pre-dose of day 2

  6. Time delay between the time of dosing and time of appearance of concentration in the sampling compartment (tlag) of multiple dose regimen - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: Pre-dose on day 2 ]
    The parameter mentioned above parameters was based on assessments starting with pre-dose of day 2

  7. Minimum observed serum concentration at the end of the dosage interval (Ctrough) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On days 2, 3, 4, 5, and 6 ]
    PD parameter was assessed at pre-dose visit on days 2, 3, 4, 5, and 6 - - No results available

  8. Area Under the Curve (AUC) [0-24] for the single dose regimen and the first day of multiple dose regimen - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: AUC [0-24] as "area under the serum concentration" versus time curve from time 0 hours to pre-dose value of the Days 1, 2, 3, 4, 5, 6 calculated by the linear trapezoidal rule ]
    Values below the level of quantitation will be set to 0. Values below the baseline concentration will be set to zero other than for the values for which no later values above the baseline concentration are available, which will be set to missing

  9. Area Under the Curve (AUC) 0-tlast for the multiple dose regimen - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: From time 0 hour to the last data point (tlast) at Day 16 after drug administration ]
    This is derived as area under the serum concentration versus time curve from time 0 h to the last data point tlast after drug administration above the limit of quantitation and the baseline concentration, calculated by the linear trapezoidal rule

  10. Area Under the Curve (AUC) for the multiple dose regimen - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: Day 2 ]
    AUC will be derived as area under the serum concentration versus time curve extrapolated to infinity, calculated as AUC = AUC0-tlast + Clast/λz

  11. Peak Plasma Concentration (Cmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On day -1 ]
    The parameter mentioned above was measured without treatment, based on assessments on day -1

  12. Time to reach Cmax (tmax) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On day -1 ]
    The parameter mentioned above was measured without treatment, based on assessments on day -1

  13. Time delay between the time of dosing and time of appearance of concentration in the sampling compartment (tlag) - Most of the subjects below limit of quantification pharmacokinetic parameter not calculable [ Time Frame: On day -1 ]
    The parameter mentioned above was measured without treatment, based on assessments on day -1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To be eligible for inclusion into this study, each subject must fulfil the following inclusion criteria.Each subject must meet all of the following inclusion criteria at the pre-study Screening visit (within 20 days prior to admission in the Unit for the dosing period) in order to participate in this study.

  1. Male or female subjects of Japanese ethnicity, aged between 18 and 60 years inclusive, who must have all four Japanese grandparents who were born in Japan.
  2. Subject has to be able to communicate well with the investigator, understands and complies with the requirements of the study, and understands and signs the written volunteer informed consent form.
  3. Subject's systemic and ocular medical history must be considered normal in the opinion of the investigator at the Screening and Baseline visits.
  4. Best corrected distance visual acuity (BCDVA) score ≤ 0.00 LogMAR (≥83 ETDRS letters, 20/20 Snellen or 1.0 decimal fraction) in each eye at the Screening and Baseline visits.
  5. Normal anterior segment on external and slit lamp examination in both eyes at the Screening and Baseline visits.
  6. Normal posterior segment on fundus ophthalmoscopic examination in both eyes at the Screening and Baseline visits.
  7. Subject must be considered in good systemic health in the opinion of the investigator at the Screening and Baseline visits, as determined by:

    1. Subject's body mass index is between 18.5 and 30.4 kg/m2 inclusive
    2. A pre-study physical examination with no clinically significant abnormalities.
    3. Vital signs within clinically acceptable ranges for the purposes of the study (sitting systolic blood pressure [BP] ≥ 90 mmHg and ≤ 150 mmHg; diastolic BP ≥ 50 mmHg and ≤ 95 mmHg; heart rate ≥ 40 and ≤ 100 beats per minute; oral body temperature ≥ 35.5°C and ≤ 37.5°C).
    4. An ECG with no clinically significant abnormalities.
    5. Pre-study clinical laboratory findings within normal range or not deemed clinically significant in the opinion of the investigator if outside of the normal range
  8. Woman subject who meets the criteria for post-menopausal stage (post menopause is defined as the period following peri-menopause, i.e. postmenopausal after 12 months without a menstrual period and with a serum FSH value within the reference range for postmenopausal females at Screening) or permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or woman subject using oral, injected or implanted hormonal methods of contraception or with a double barrier methods of contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. A female condom and a male condom should not be used together as friction between the two can result in either product failing.
  9. Male subjects with female partners of child-bearing potential must use 2 different forms of highly effective contraception throughout the study and for a further 3 months after the follow-up visit and all male subjects must be willing to avoid donating sperm during this time. The following methods of contraception are considered to be highly effective: established use of oral, injected or implanted hormonal contraception; placement of an intrauterine device or intrauterine system; use of a barrier method of contraception (condom or occlusive cap with use of a spermicide); male sterilisation (post-vasectomy documentation of the absence of sperm in the ejaculate must be provided).

Exclusion Criteria:

Subjects meeting any of the following criteria at Screening will be excluded from entry into the study:

  1. Subject has had a clinically significant illness in the 6 weeks before screening in the opinion of the investigator.
  2. Subject is not suitable to participate in the study in the opinion of the investigator
  3. Subject has participated in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing.
  4. Subject has had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or has a clinically significant allergy to drugs, foods or other materials (in the opinion of the investigator).
  5. Administration of any topical ocular (prescription or over the counter including artificial tears) or systemic medication including herbal product or fish oil preparations within 14 days before the first dose of study drug. Vitamins and mineral supplements not containing other substances are allowed until 96 hours before each dose if considered by the Investigator unlikely to interfere with the study results. Paracetamol at doses of at most 2 grams per day and ibuprofen at doses of at most 1200 mg per day for no more than 3 consecutive days or 6 non-consecutive days are allowed. Oral, injectable and implantable hormonal contraceptives are allowed without restrictions for female subjects. Longer exclusion periods apply for:

    1. amiodarone and hydroxychloroquine (210 days),
    2. monoclonal antibodies/ immunoglobulins/ other therapeutic proteins (120 days)
    3. Experimental drugs with a half life known to the Study Unit: Five half lives plus 2 weeks
    4. Experimental drugs with a half-life unknown to the Study Unit: 120 days
    5. chloroquine and flunarizine (100 days)
    6. fluoxetine (75 days),
    7. benzodiazepines different from midazolam, lorazepam and triazolam, chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone, carbamazepine, phenytoin and phenprocoumon (35 days).
  6. Subject has a significant history of drug/solvent abuse or a positive drugs of abuse test at any time during the study.
  7. Subject has a history of alcohol abuse or currently drinks in excess of 28 units per week or has a positive alcohol breath test at any time during the study.
  8. Subject is a smoker or has smoked in the 6 months prior to dosing.
  9. Subject who has a positive human immunodeficiency virus (HIV) screen, hepatitis B screen or hepatitis C screen.
  10. Subject has donated blood or blood products (e.g., plasma or platelets) within the 3 months prior to screening.
  11. Subject has a partner who will be pregnant or breastfeeding during the study
  12. Pregnant or breastfeeding female or those with a positive pregnancy test or who will not use a medically acceptable contraceptive method from selection and during the study
  13. Subject having used corticosteroid sporadically in the last 30 days whichever the route of administration, or any medication by ocular or nasal administration route
  14. Subjects diagnosed with any ocular disease other than refractive error
  15. Subject with history of ocular surgery, including laser refractive surgery
  16. Subject using a contact lens within 7 days prior administration of the first dose
  17. Intraocular pressure (IOP) ≥ 22 mmHg in either eye at screening or baseline
  18. Presence of any corneal opacity or corneal fluorescein staining >0.5 grade using the modified Oxford scale in either eye at screening or baseline
  19. Schirmer's test without anesthesia ≤ 9 mm/5 minutes in either eye at screening or baseline
  20. Tear film break up time (TFBUT) < 8 seconds in either eye at screening or baseline Note: Alcoholic beverages should not be taken from 48 h before first drug administration until discharge from the Study center.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03836859


Locations
United States, California
WCCT Global
Cypress, California, United States, 90630
Sponsors and Collaborators
Dompé Farmaceutici S.p.A
Cromsource
Investigators
Study Director: Flavio Mantelli, MD, PhD Dompé SpA Milan

Responsible Party: Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier: NCT03836859     History of Changes
Other Study ID Numbers: NGF0117
First Posted: February 11, 2019    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: January 2019

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Keratitis
Corneal Diseases
Eye Diseases